NCT01226420终止2 期
A Phase II, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 3
- 主要终点
- Efficacy
研究概览
简要总结
Alefacept is a drug tht may reduce the number of T cells in circulation. This drug has been used in the treatment of psoriasis, which is a skin disorder also caused by T cells, like chronic GVHD. Information from studies in psoriasis and in other patients with GVHD suggests that this drug may help to treat chronic GVHD. Chronic GVHD is a medical condition that can develop after allogeneic stem cell transplantation. It occurs when the donor immune cells (the "graft") attack and damage organs and tissue (the "host"). It is thought that T cells, a subtype of immune cells, are responsible for the tissue damage in chronic GVHD. In this research study we are looking to see how well Alefacept works in treating chronic GVHD that has not resolved after therapy with corticosteroids.
详细描述
- During the first week of treatment, participants will receive 2 doses of Alefacept intravenously (Day 1 and Day 4). During weeks 2-12, Alefacept will be given subcutaneously once weekly.
- On weeks 1, 2 and every other week through Week 12 of study treatment, participants will have a physical exam, blood tests, and be asked general health and specific questions about any problems they may be having.
- Every other week, participants will be asked to complete a questionnaire about their physical symptoms, activity level and emotional well being.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older
- •Diagnosed with cGVHD according to NIH criteria
- •Active cGVHD despite treatment with corticosteroids AND one additional immunosuppressive agent for at least 4 weeks, within 52 weeks of enrollment.
- •Subject is a recipient of related or unrelated BMT or PBSCT
- •Subject underwent transplantation at least 6 months prior to enrollment
- •Subject is on stable immunosuppressive regimen for 2 weeks prior to enrollment. Adjustment of immunosuppressive medications to maintain a therapeutic level is permitted.
- •Female of child bearing potential must have a negative pregnancy test prior to first dose of alefacept and must agree to practice effective contraception during the study. Men must also agree to use adequate contraception prior to study entry and for the duration of the study.
- •Meets medication restriction requirements and agrees to follow medications restrictions during study.
排除标准
- •Received donor lymphocyte infusions in the preceding 100 days
- •Currently undergoing ECP
- •Subject is recipient of related or unrelated UCB
- •Subject has bronchiolitis obliterans, bronchiolitis obliterans with organizing pneumonia or cryptogenic organizing pneumonia as the sole manifestation of cGVHD
- •Uncontrolled intercurrent active infection.
- •Absolute neutrophil count < 1000/L
- •AST, ALT or total bilirubin > 2x institutional upper limit of normal unless this is a manifestation of GVHD
- •Recurrent or progressive malignancy at any time after HCT, as applicable for the individual malignancy
- •Subject was in any clinical study within the last 30 days
- •Receipt of 5 or more prior agents to treat cGVHD
- •Known hypersensitivity to alefacept or any components of the study medication
- •Known to be positive for human immunodeficiency virus (HIV) antibodies
- •Currently enrolled in any other study for chronic GVHD treatment and receiving treatment under the study or previous participation in this study.
- •Pregnant or nursing
- •Concurrent illness which, in the opinion of the Investigator, may interfere with treatment or evaluation of safety
研究组 & 干预措施
Alefacept
Experimental
Alefacept iv
干预措施: Alefacept (Drug)
结局指标
主要结局
Efficacy
时间窗: 2 years
Proportion of patients with a favorable response, defined as a complete or partial remission at week 12 as compared to baseline in subjects with steroid refractory cGVHD.
次要结局
- Safety of Alefacept Infusions in Patients With Chronic GVHD.(2 years)
研究者
Corey S. Cutler, MD, MPH
Principal Investigator
Dana-Farber Cancer Institute
研究点 (3)
Loading locations...
相似试验
终止
1 期
Alefacept in Patients With Relapsed/Refractory Aplastic AnemiaAplastic AnemiaNCT01267643The Cleveland Clinic4
招募中
2 期
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesHematologic MalignancyRemissionTP53Intrachromosomal Amplification of Chromosome 21Cytogenetic AbnormalityCNS LeukemiaAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplasiaJuvenile Myelomonocytic LeukemiaSomatic MutationPTPN11 Gene MutationN-RAS Gene AmplificationNeurofibromatosis 1NF1 MutationCBL Gene MutationMonosomy 7Fetal HemoglobinChromosome AbnormalityLymphoblastic LymphomaHigh Grade Non-Hodgkin's Lymphoma, AdultAMLAcute LeukemiaMinimal Residual DiseaseNCT05735717Masonic Cancer Center, University of Minnesota70
已完成
不适用
Alefacept in Patients With Severe Scalp Alopecia AreataAlopecia AreataNCT00167102University of Minnesota45
已完成
2 期
Effect of Telitacicept on Antibody Titers in Primary APS PatientsAntiphospholipid Syndrome (APS)NCT06315530Ruijin Hospital20
已完成
2 期
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic DisordersAllogeneic Stem Cell TransplantNon-HodgkinsLymphoblastic LymphomaLeukemiaParoxysmal Nocturnal Hemoglobinuria (PNH)Myelodysplastic SyndromeNCT00587054Memorial Sloan Kettering Cancer Center129